Pfizer’s celebrated Covid-19 vaccine freezes many people out — but a rival mRNA team says they thawed out a solution

John Carroll

Editor & Founder

Once the euphoria began to wane a bit following Pfizer’s dramatic unveiling of a 90%-plus effectiveness rate from its pivotal Covid-19 vaccine study earlier …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Pfizer’s celebrated Covid-19 vaccine freezes many people out — but a rival mRNA team says they thawed out a solution

John Carroll

Editor & Founder

Sign up to read this article for free.

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock

Pfiz­er’s cel­e­brat­ed Covid-19 vac­cine freezes many peo­ple out — but a ri­val mR­NA team says they thawed out a so­lu­tion

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

Pfizer’s celebrated Covid-19 vaccine freezes many people out — but a rival mRNA team says they thawed out a solution

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock